Skip to main content
CHRS
NASDAQ Life Sciences

Coherus Oncology Reports Q1 Results, LOQTORZI Revenue Growth, and Pipeline Progress; Finalizes $53.6M Offering

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.86
Mkt Cap
$300.724M
52W Low
$0.71
52W High
$2.616
52W Position info
162% above low
Off High info
29% below high
Rel. Volume info
2.6× avg
Market data snapshot near publication time

CHRS has more than doubled off its 52-week low of $0.71 on elevated volume (2.6× avg).

Summary

Coherus Oncology reported Q1 2026 financial results, showing year-over-year LOQTORZI revenue growth and significant pipeline progress, while also finalizing a $53.6 million public offering.


Key Events · Earnings and Guidance · CHRS

  • Q1 2026 Financial Results

    Net revenue from continuing operations was $12.3 million, with LOQTORZI net revenue reaching $11.8 million, a 61% increase over Q1 2025. Net loss from continuing operations improved to $36.9 million, or $(0.27) per share, compared to $(0.41) per share in Q1 2025.

  • LOQTORZI Commercial Performance

    The company achieved its highest volume of new patient starts to date for LOQTORZI, despite a 5% sequential decrease in revenue from Q4 2025, attributed to severe weather and seasonality.

  • Pipeline Advancement

    Enrollment is complete for the Phase 2 trial of casdozokitug in 1L uHCC, with initial data expected mid-2026. Multiple Phase 1b studies for tagmokitug are underway, with data readouts anticipated in mid-2026 and 2H 2026.

  • Public Offering Finalized

    During Q1 2026, Coherus sold 32.89 million shares in a public offering, including the full exercise of the underwriters' over-allotment option, generating net proceeds of $53.6 million. This updates the previously reported proceeds of $47.0 million.


Analysis · CHRS · Life Sciences

This 8-K provides a comprehensive update on Coherus Oncology's first-quarter performance, highlighting progress in its strategic pivot to oncology. The company reported increased LOQTORZI revenue year-over-year and significant advancements in its pipeline, with key clinical trial milestones approaching. The filing also finalizes the details of a substantial public offering completed in Q1, which provided crucial capital to support ongoing operations and development. While the company continues to operate at a loss, the execution on its oncology strategy and pipeline progress are important for its long-term outlook.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CHRS was trading at $1.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $300.7M. The 52-week trading range was $0.71 to $2.62. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CHRS - Latest Insights

CHRS
Nov 09, 2026, 4:59 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.8008
Real-time Price: $0.4942 info
Change: -$0.3066 (-38%) info
Market Cap: $76.357M info
CHRS
Nov 09, 2026, 4:20 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.7976
Real-time Price: $0.4942 info
Change: -$0.3034 (-38%) info
Market Cap: $76.357M info
CHRS
Nov 09, 2026, 4:07 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.770
Real-time Price: $0.4942 info
Change: -$0.2758 (-36%) info
Market Cap: $76.357M info
CHRS
Oct 29, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.05
Real-time Price: $0.4942 info
Change: -$0.5558 (-53%) info
Market Cap: $76.357M info
CHRS
Sep 23, 2026, 1:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.25
Real-time Price: $0.4942 info
Change: -$0.7508 (-60%) info
Market Cap: $76.357M info